journal
MENU ▼
Read by QxMD icon Read
search

PharmacoEconomics

journal
https://www.readbyqxmd.com/read/28432642/emerging-use-of-early-health-technology-assessment-in-medical-product-development-a-scoping-review-of-the-literature
#1
REVIEW
Maarten J IJzerman, Hendrik Koffijberg, Elisabeth Fenwick, Murray Krahn
Early health technology assessment is increasingly being used to support health economic evidence development during early stages of clinical research. Such early models can be used to inform research and development about the design and management of new medical technologies to mitigate the risks, perceived by industry and the public sector, associated with market access and reimbursement. Over the past 25 years it has been suggested that health economic evaluation in the early stages may benefit the development and diffusion of medical products...
April 21, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28391508/response-to-letter-to-the-editor-regarding-abiraterone-acetate-for-the-treatment-of-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#2
LETTER
Bram L T Ramaekers, Rob Riemsma, Florian Tomini, Thea van Asselt, Sohan Deshpande, Steven Duffy, Nigel Armstrong, Johan L Severens, Jos Kleijnen, Manuela A Joore
No abstract text is available yet for this article.
April 8, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28390016/comment-on-abiraterone-acetate-for-the-treatment-of-chemotherapy-na%C3%A3-ve-metastatic-castration-resistant-prostate-cancer-an-evidence-review-group-perspective-of-an-nice-single-technology-appraisal
#3
LETTER
Odette Reifsnider, Fiona Hall, Sonja Sorensen, Irina Proskorovsky, Isabelle Girod, Jennifer Lee
No abstract text is available yet for this article.
April 8, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28378193/regression-based-approaches-to-patient-centered-cost-effectiveness-analysis
#4
Daisuke Goto, Ya-Chen Tina Shih, Pascal Lecomte, Melvin Olson, Chukwukadibia Udeze, Yujin Park, C Daniel Mullins
Achieving comprehensive patient centricity in cost-effectiveness analyses (CEAs) requires a statistical approach that accounts for patients' preferences and clinical and demographic characteristics. Increased availability and accessibility of patient-level health-related utility data from clinical trials or observational database provide enhanced opportunities to conduct more patient-centered CEA. Regression-based approaches that incorporate patient-level data hold great promise for enhancing CEAs to be more patient centered; this paper provides guidance regarding two CEA approaches that apply regression-based approaches utilizing patient-level health-related utility and costs data...
April 4, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28374325/discrete-choice-experiments-a-guide-to-model-specification-estimation-and-software
#5
Emily Lancsar, Denzil G Fiebig, Arne Risa Hole
We provide a user guide on the analysis of data (including best-worst and best-best data) generated from discrete-choice experiments (DCEs), comprising a theoretical review of the main choice models followed by practical advice on estimation and post-estimation. We also provide a review of standard software. In providing this guide, we endeavour to not only provide guidance on choice modelling but to do so in a way that provides a 'way in' for researchers to the practicalities of data analysis. We argue that choice of modelling approach depends on the research questions, study design and constraints in terms of quality/quantity of data and that decisions made in relation to analysis of choice data are often interdependent rather than sequential...
April 3, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28342114/using-parameter-constraints-to-choose-state-structures-in-cost-effectiveness-modelling
#6
Howard Thom, Chris Jackson, Nicky Welton, Linda Sharples
BACKGROUND: This article addresses the choice of state structure in a cost-effectiveness multi-state model. Key model outputs, such as treatment recommendations and prioritisation of future research, may be sensitive to state structure choice. For example, it may be uncertain whether to consider similar disease severities or similar clinical events as the same state or as separate states. Standard statistical methods for comparing models require a common reference dataset but merging states in a model aggregates the data, rendering these methods invalid...
March 24, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28342113/crizotinib-for-untreated-anaplastic-lymphoma-kinase-positive-non-small-cell-lung-cancer-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#7
REVIEW
Philip Morgan, Nerys Woolacott, Mousumi Biswas, Teumzghi Mebrahtu, Melissa Harden, Robert Hodgson
As part of the National Institute for Health and Care Excellence (NICE) single technology appraisal process, the manufacturer of crizotinib submitted evidence on the clinical and cost effectiveness of crizotinib in untreated anaplastic lymphoma kinase-positive (ALK-positive) non-small-cell lung cancer (NSCLC). Crizotinib has previously been assessed by NICE for patients with previously treated ALK-positive NSCLC (TA 296). It was not approved in this previous appraisal, but had been made available through the cancer drugs fund...
March 24, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28342112/an-investigation-of-the-overlap-between-the-icecap-a-and-five-preference-based-health-related-quality-of-life-instruments
#8
Lidia Engel, Duncan Mortimer, Stirling Bryan, Scott A Lear, David G T Whitehurst
BACKGROUND: The ICEpop CAPability measure for Adults (ICECAP-A) is a measure of capability wellbeing developed for use in economic evaluations. It was designed to overcome perceived limitations associated with existing preference-based instruments, where the explicit focus on health-related aspects of quality of life may result in the failure to capture fully the broader benefits of interventions and treatments that go beyond health. The aim of this study was to investigate the extent to which preference-based health-related quality of life (HRQoL) instruments are able to capture aspects of capability wellbeing, as measured by the ICECAP-A...
March 24, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28337720/defining-value-the-need-for-a-longer-broader-view
#9
LETTER
Tomas J Philipson, Sachin Kamal-Bahl, Anupam B Jena
No abstract text is available yet for this article.
March 23, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28337719/an-early-health-economic-analysis-of-the-potential-cost-effectiveness-of-an-adherence-intervention-to-improve-outcomes-for-patients-with-cystic-fibrosis
#10
Paul Tappenden, Susannah Sadler, Martin Wildman
BACKGROUND: Cystic fibrosis (CF) negatively impacts upon health-related quality of life and survival. Adherence to nebulised treatments is low; improving adherence is hypothesised to reduce rates of exacerbation requiring intravenous antibiotics and lung function decline. OBJECTIVE: A state transition model was developed to assess the cost effectiveness of an intervention aimed at increasing patient adherence to nebulised and inhaled antibiotics compared with current CF care, in advance of the forthcoming CFHealthHub randomised controlled trial (RCT)...
March 23, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28321640/how-qualitative-methods-can-be-used-to-inform-model-development
#11
Samantha Husbands, Susan Jowett, Pelham Barton, Joanna Coast
Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modellers find most challenging. Further, it is important that modelling methods and related guidance are continually updated in light of any new approaches that could potentially enhance model credibility...
March 20, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28316007/talimogene-laherparepvec-for-treating-metastatic-melanoma-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#12
REVIEW
Nigel Fleeman, Adrian Bagust, Angela Boland, Sophie Beale, Marty Richardson, Ashma Krishan, Angela Stainthorpe, Ahmed Abdulla, Eleanor Kotas, Lindsay Banks, Miranda Payne
The National Institute for Health and Care Excellence (NICE) invited the manufacturer (Amgen) of talimogene laherparepvec (T-VEC) to submit clinical and cost-effectiveness evidence for previously untreated advanced (unresectable or metastatic) melanoma as part of the Institute's Single Technology Appraisal process. The Liverpool Reviews and Implementation Group (LRiG) at the University of Liverpool was commissioned to act as the Evidence Review Group (ERG). This article presents a summary of the company's submission of T-VEC, the ERG review and the resulting NICE guidance (TA410), issued in September 2016...
March 18, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28247184/bayesian-methods-for-calibrating-health-policy-models-a-tutorial
#13
Nicolas A Menzies, Djøra I Soeteman, Ankur Pandya, Jane J Kim
Mathematical simulation models are commonly used to inform health policy decisions. These health policy models represent the social and biological mechanisms that determine health and economic outcomes, combine multiple sources of evidence about how policy alternatives will impact those outcomes, and synthesize outcomes into summary measures salient for the policy decision. Calibrating these health policy models to fit empirical data can provide face validity and improve the quality of model predictions. Bayesian methods provide powerful tools for model calibration...
February 28, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28238151/are-quality-adjusted-life-years-a-good-proxy-measure-of-individual-capabilities
#14
Paul Mark Mitchell, Sridhar Venkatapuram, Jeff Richardson, Angelo Iezzi, Joanna Coast
BACKGROUND: There is a debate in the health economics literature concerning the most appropriate way of applying Amartya Sen's capability approach in economic evaluation studies. Some suggest that quality-adjusted life years (QALYs) alone are adequate while others argue that this approach is too narrow and that direct measures of capability wellbeing provide a more extensive application of Sen's paradigm. OBJECTIVE: This paper empirically explores whether QALYs provide a good proxy for individual capabilities...
February 25, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28176188/adalimumab-for-treating-moderate-to-severe-hidradenitis-suppurativa-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#15
REVIEW
Paul Tappenden, Christopher Carroll, John W Stevens, Andrew Rawdin, Sabine Grimm, Mark Clowes, Eva Kaltenthaler, John R Ingram, Fiona Collier, Mohammad Ghazavi
As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of adalimumab (AbbVie) to submit evidence on the clinical effectiveness and cost effectiveness of adalimumab for the treatment of moderate-to-severe hidradenitis suppurativa (HS). The appraisal assessed adalimumab as monotherapy in adult patients with an inadequate response to conventional systemic HS therapy. The School of Health and Related Research Technology Appraisal Group was commissioned to act as the independent Evidence Review Group (ERG)...
February 7, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28324439/authors-reply-to-gandjour-can-the-evidem-framework-tackle-issues-raised-by-evaluating-treatments-for-rare-diseases-analysis-of-issues-and-policies-and-context-specific-adaptation
#16
LETTER
https://www.readbyqxmd.com/read/28324438/comment-on-can-the-evidem-framework-tackle-issues-raised-by-evaluating-treatments-for-rare-diseases-analysis-of-issues-and-policies-and-context-specific-adaptation
#17
LETTER
https://www.readbyqxmd.com/read/28285379/evolocumab-for-treating-primary-hypercholesterolaemia-and-mixed-dyslipidaemia-an-evidence-review-group-perspective-of-a-nice-single-technology-appraisal
#18
Christopher Carroll, Paul Tappenden, Rachid Rafia, Jean Hamilton, Duncan Chambers, Mark Clowes, Paul Durrington, Nadeem Qureshi, Anthony S Wierzbicki
As part of its single technology appraisal (STA) process, the UK National Institute for Health and Care Excellence (NICE) invited the manufacturer of evolocumab (Amgen) to submit evidence on the clinical and cost effectiveness of evolocumab. The appraisal assessed evolocumab as monotherapy or in combination with a statin with or without ezetimibe, or in combination with ezetimibe (without statin therapy), in adult patients with primary hypercholesterolaemia (which includes mixed dyslipidaemia), for whom statins do not provide optimal control of their low-density lipoprotein cholesterol (LDL-C) levels and/or for whom statins are contraindicated or not tolerated...
May 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28210864/pharmacy-benefit-management-companies-do-they-create-value-in-the-us-healthcare-system
#19
Alan Lyles
Pharmacy benefit management companies (PBMs) perform functions in the US market-based healthcare system that may be performed by public agencies or quasi-public institutions in other nations. By aggregating lives covered under their many individual contracts with payers, PBMs have formidable negotiating power. They influence pharmaceutical insurance coverage, design the terms of coverage in a plan's drug benefit, and create competition among providers for inclusion in a plan's network. PBMs have, through intermediation, the potential to secure lower drug prices and to improve rational prescribing...
May 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/28205150/the-potential-cost-effectiveness-of-different-dengue-vaccination-programmes-in-malaysia-a-value-based-pricing-assessment-using-dynamic-transmission-mathematical-modelling
#20
Asrul Akmal Shafie, Hui Yee Yeo, Laurent Coudeville, Lucas Steinberg, Balvinder Singh Gill, Rohani Jahis, Amar-Singh Hss
BACKGROUND: Dengue disease poses a great economic burden in Malaysia. METHODS: This study evaluated the cost effectiveness and impact of dengue vaccination in Malaysia from both provider and societal perspectives using a dynamic transmission mathematical model. The model incorporated sensitivity analyses, Malaysia-specific data, evidence from recent phase III studies and pooled efficacy and long-term safety data to refine the estimates from previous published studies...
May 2017: PharmacoEconomics
journal
journal
31126
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"